 MARLBOROUGH, Mass., March 11, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced it will present new study data regarding the direct drug application of its product candidate, PH-762, at the AACR Annual Meeting 2021. 